Akero Therapeutics, Inc. (NASDAQ:AKRO) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) have been given a consensus rating of “Moderate Buy” by the eight ratings firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $46.83.

Several research firms have commented on AKRO. HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Akero Therapeutics in a research report on Monday, November 18th. Citigroup assumed coverage on shares of Akero Therapeutics in a research report on Monday, November 18th. They set a “buy” rating and a $65.00 price target on the stock.

Insider Buying and Selling

In other Akero Therapeutics news, insider Catriona Yale sold 9,061 shares of the business’s stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $27.73, for a total transaction of $251,261.53. Following the completion of the sale, the insider now directly owns 74,158 shares in the company, valued at approximately $2,056,401.34. The trade was a 10.89 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Andrew Cheng sold 24,992 shares of the firm’s stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $31.14, for a total value of $778,250.88. Following the completion of the transaction, the chief executive officer now owns 605,417 shares in the company, valued at approximately $18,852,685.38. This trade represents a 3.96 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 386,802 shares of company stock valued at $12,114,600. 7.94% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Akero Therapeutics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock worth $71,000 after buying an additional 446 shares in the last quarter. Eastern Bank acquired a new stake in Akero Therapeutics in the 3rd quarter valued at about $100,000. Summit Financial Wealth Advisors LLC acquired a new stake in Akero Therapeutics in the 3rd quarter valued at about $205,000. Victory Capital Management Inc. purchased a new position in Akero Therapeutics in the 3rd quarter worth approximately $211,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Akero Therapeutics during the 3rd quarter worth approximately $265,000.

Akero Therapeutics Stock Down 0.5 %

AKRO stock opened at $27.82 on Thursday. The company has a market capitalization of $1.94 billion, a P/E ratio of -7.42 and a beta of -0.23. Akero Therapeutics has a 12 month low of $15.32 and a 12 month high of $37.00. The firm’s fifty day simple moving average is $30.57 and its 200-day simple moving average is $27.79. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25.

Akero Therapeutics (NASDAQ:AKRO) last announced its quarterly earnings results on Friday, November 8th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.15). As a group, equities research analysts forecast that Akero Therapeutics will post -3.96 earnings per share for the current year.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.